Neurofibrillary labels
US7335652B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 22, 2003 |
| Grant date | Feb 26, 2008 |
| Priority date | — |
| Expiry date | Feb 20, 2025 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/6896
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Disclosed are methods for determining the stage of neurofibrillary degeneration associated with a tauopathy in a subject believed to suffer from the disease, by (i) introducing into the subject a ligand capable of labeling aggregated paired helical filament (PHF) tau protein, (ii) determining the presence and/or amount of ligand bound to extracellular aggregated PHF tau in the medial temporal lobe of the brain of the subject, (iii) correlating the result of the determination made in (ii) with the extent of neurofibrillary degeneration in the subject. The methods can be used for pre-mortem diagnosis and staging of tauopathies such as Alzheimer's Disease. Preferred ligands include sulphonated-benzothiazole-like compounds and diaminophenothiazines.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.